Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ADPKD Clear all
Recruiting Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

NCT07228364
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

NCT02616055
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 62 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 9, 2026, 3:15 AM EDT
Recruiting Not applicable Interventional

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

NCT07454174
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Ren-Nu and KetoCitra
Dietary Supplement
Lead sponsor
Richard Fatica
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Recruiting Phase 2 Interventional

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
ABBV-CLS-628, Placebo
Drug
Lead sponsor
Calico Life Sciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Recruiting No phase listed Observational

ADPKD Patient Registry

NCT04039061
View directory record Official record
Conditions
Polycystic Kidney Diseases
Interventions
Not listed
Lead sponsor
PKD Foundation
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 9, 2026, 3:15 AM EDT
Completed No phase listed Observational

Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease

NCT01114594
View directory record Official record
Conditions
Chronic Kidney Disease, Polycystic Kidney, Autosomal Dominant
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 9, 2026, 3:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

NCT03523728
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 9, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

NCT03493802
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 9, 2026, 3:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Early PKD Observational Cohort Study

NCT02936791
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
4 Years to 35 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 9, 2026, 3:15 AM EDT
Terminated Phase 3 Interventional Results available

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

NCT05208866
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RGLS8429 in Healthy Volunteers

NCT05429073
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RGLS8429, Placebo volume-matching RGLS8429 dose
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 9, 2026, 3:15 AM EDT
Completed No phase listed Observational

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT01430494
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
12 Years to 70 Years
Enrollment
3,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
102
States / cities
Peoria, Arizona • Tempe, Arizona • Azusa, California + 89 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Not applicable Interventional Results available

Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease

NCT03342742
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Weight Loss
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT02251275
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 9, 2026, 3:15 AM EDT
Not yet recruiting Phase 2 Interventional

Bempedoic Acid Therapy for Polycystic Kidney Disease

NCT07282821
View directory record Official record
Conditions
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
Drug
Lead sponsor
Kenneth Hallows
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 9, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Testing in Autosomal Dominant Polycystic Kidney Disease

NCT06085807
View directory record Official record
Conditions
ADPKD
Interventions
Survey
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT04284657
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Pravastatin, sodium citrate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 9, 2026, 3:15 AM EDT
Completed No phase listed Observational

Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease

NCT01039987
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 9, 2026, 3:15 AM EDT
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 9, 2026, 3:15 AM EDT
Completed No phase listed Observational

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

NCT04407481
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 9, 2026, 3:15 AM EDT